<p>根据最近向证券交易委员会提交的文件，Principal Financial Group Inc. 在第三季度将其在 ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - 免费报告) 的持股减少了 34.7%。该公司在此期间出售了 52,316 股后，持有 98,489 股这家专业制药公司的股票。截至其最近的 SEC 文件，Principal Financial Group Inc. 拥有约 0.45% 的 ANI Pharmaceuticals，价值 9,022,000 美元。</p>
<p>获取 <strong>ANI Pharmaceuticals</strong> 的提醒：</p>
<p>其他几家机构投资者和对冲基金最近也调整了对 ANIP 的持股。Advisors Asset Management Inc. 在第一季度购买了约 28,000 美元的新头寸。Caitong International Asset Management Co. Ltd 在第二季度将其在 ANI Pharmaceuticals 的股份增加了 4,636.4%。Caitong International Asset Management Co. Ltd 现在拥有 521 股这家专业制药公司的股票，价值 34,000 美元，此前在此期间又购买了 510 股。Newbridge Financial Services Group Inc. 在第二季度将其在 ANI Pharmaceuticals 的股份增加了 200.0%。Newbridge Financial Services Group Inc. 现在拥有 600 股这家专业制药公司的股票，价值 39,000 美元，此前在上个季度又购买了 400 股。怀俄明州购买了约 50,000 美元的新头寸。最后，CWM LLC 在第三季度将其在 ANI Pharmaceuticals 的股份增加了 159.1%。CWM LLC 现在拥有 798 股这家专业制药公司的股票，价值 73,000 美元，此前在此期间又获得了 490 股。对冲基金和其他机构投资者持有该公司 76.05% 的股票。</p>
<h2>ANI Pharmaceuticals 股票表现</h2>
<p>NASDAQ:ANIP 周五开盘价为 76.70 美元。该公司的 50 日移动平均价格为 81.26 美元，200 日移动平均价格为 85.77 美元。该公司的流动比率为 2.58，速动比率为 2.04，债务与股本比率为 1.20。该公司的市值为 17.2 亿美元，市盈率为 47.06，贝塔值为 0.50。ANI Pharmaceuticals, Inc. 的 12 个月最低价为 54.10 美元，最高价为 99.50 美元。</p>
<h2>ANI Pharmaceuticals 内部交易</h2>
<p>在其他新闻中，副总裁 Meredith Cook 在 1 月 13 日星期二出售了 500 股公司的股票。股票以平均价格 84.33 美元出售，总价值为 42,165.00 美元。交易完成后，副总裁直接持有 74,374 股公司股票，价值 6,271,959.42 美元。这代表其持股减少了 0.67%。该交易已在向证券交易委员会提交的文件中披露，具体信息可在此链接查看。此外，董事 Renee P. Tannenbaum 在 12 月 5 日星期五出售了 1,800 股 ANI Pharmaceuticals 的股票。股票以平均价格 81.15 美元出售，总价值为 146,070.00 美元。交易完成后，董事持有 25,157 股公司股票，价值约 2,041,490.55 美元。该交易使其持股减少了 6.68%。有关此销售的更多详细信息可在官方 SEC 披露中找到。过去 90 天内，内部人士共出售了 4,322 股公司股票，价值 354,816 美元。内部人士持有公司 11.10% 的股票。</p>
<h2>分析师评级调整</h2>
<p>几位股票分析师对 ANIP 股票发布了报告。Weiss Ratings 在 12 月 29 日的报告中重申了对 ANI Pharmaceuticals 股票的 “持有（c+）” 评级。Guggenheim 在 1 月 16 日的研究报告中将 ANI Pharmaceuticals 的目标价从 115.00 美元上调至 124.00 美元，并给予该股票 “买入” 评级。Barclays 在 12 月 9 日的研究报告中开始覆盖 ANI Pharmaceuticals 的股票。他们对该股票给予了 “增持” 评级，并设定了 100.00 美元的目标价。最后，Zacks Research 在 1 月 6 日的报告中将 ANI Pharmaceuticals 的评级从 “强力买入” 下调至 “持有”。六位股票研究分析师对该股票给予了买入评级，三位分析师对公司给予了持有评级。根据 MarketBeat 的数据，ANI Pharmaceuticals 目前的共识评级为 “适度买入”，平均目标价为 103.43 美元。</p>
<p><strong>查看我们关于 ANIP 的最新研究报告</strong></p>
<h2>关于 ANI Pharmaceuticals</h2>
<p>（免费报告）</p>
<p>ANI Pharmaceuticals, Inc. 是一家总部位于美国的专业制药公司，专注于仿制药和品牌处方药的开发、生产和商业化。该公司作为一个端到端的服务提供商，提供从活性药物成分（API）生产和配方开发到成品剂型制造和包装的服务。</p>
<p>ANI 的产品组合涵盖了多个治疗领域的注射和口服疗法，包括内分泌学、肿瘤学、疼痛管理和呼吸护理。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票，而不是 ANI Pharmaceuticals</li>
<li>Nvidia CEO 发布大胆的特斯拉预测</li>
<li>你的银行账户不再安全</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>新的黄金价格目标</li>
</ul>
<p><strong>想看看其他对冲基金持有的 ANIP 吗？</strong> 访问 HoldingsChannel.com，获取 ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - 免费报告) 的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5JUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5JUA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 ANI Pharmaceuticals 吗？</h2>
<p>在考虑 ANI Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经确定了五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 ANI Pharmaceuticals 并不在名单上。</p>
<p>虽然 ANI Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ANI制药

<p>Principal Financial Group Inc. 在第三季度将其在 ANI Pharmaceuticals, Inc. 的持股减少了 34.7%，目前持有 98,489 股，价值 9,022,000 美元。其他机构投资者也调整了他们的持仓。ANI Pharmaceuticals 的股票开盘价为 76.70 美元，市值为 17.2 亿美元。分析师的评级各不相同，普遍共识为 “适度买入”，平均目标价为 103.43 美元。内部交易包括副总裁 Meredith Cook 和董事 Renee P. Tannenbaum 的股票出售，过去 90 天内共计 4,322 股</p>

<p>Principal Financial Group Inc. cut its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 34.7% during the third quarter, according to its most recent filing with the Securities &amp; Exchange Commission. The firm owned 98,489 shares of the specialty pharmaceutical company's stock after selling 52,316 shares during the period. Principal Financial Group Inc. owned approximately 0.45% of ANI Pharmaceuticals worth $9,022,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>根据最近向证券交易委员会提交的文件，Principal Financial Group Inc. 在第三季度将其在 ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - 免费报告) 的持股减少了 34.7%。该公司在此期间出售了 52,316 股后，持有 98,489 股这家专业制药公司的股票。截至其最近的 SEC 文件，Principal Financial Group Inc. 拥有约 0.45% 的 ANI Pharmaceuticals，价值 9,022,000 美元。</p>
</div><p>Get <strong>ANI Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>ANI Pharmaceuticals</strong> 的提醒：</p>
</div><p>Several other institutional investors and hedge funds have also recently modified their holdings of ANIP. Advisors Asset Management Inc. purchased a new position in ANI Pharmaceuticals during the first quarter worth approximately $28,000. Caitong International Asset Management Co. Ltd raised its stake in shares of ANI Pharmaceuticals by 4,636.4% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 521 shares of the specialty pharmaceutical company's stock worth $34,000 after buying an additional 510 shares during the period. Newbridge Financial Services Group Inc. lifted its position in shares of ANI Pharmaceuticals by 200.0% during the 2nd quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company's stock valued at $39,000 after buying an additional 400 shares in the last quarter. State of Wyoming purchased a new position in shares of ANI Pharmaceuticals during the 2nd quarter valued at approximately $50,000. Finally, CWM LLC grew its stake in ANI Pharmaceuticals by 159.1% in the 3rd quarter. CWM LLC now owns 798 shares of the specialty pharmaceutical company's stock valued at $73,000 after acquiring an additional 490 shares during the period. Hedge funds and other institutional investors own 76.05% of the company's stock.</p>
<div class="lb-trans"><p>其他几家机构投资者和对冲基金最近也调整了对 ANIP 的持股。Advisors Asset Management Inc. 在第一季度购买了约 28,000 美元的新头寸。Caitong International Asset Management Co. Ltd 在第二季度将其在 ANI Pharmaceuticals 的股份增加了 4,636.4%。Caitong International Asset Management Co. Ltd 现在拥有 521 股这家专业制药公司的股票，价值 34,000 美元，此前在此期间又购买了 510 股。Newbridge Financial Services Group Inc. 在第二季度将其在 ANI Pharmaceuticals 的股份增加了 200.0%。Newbridge Financial Services Group Inc. 现在拥有 600 股这家专业制药公司的股票，价值 39,000 美元，此前在上个季度又购买了 400 股。怀俄明州购买了约 50,000 美元的新头寸。最后，CWM LLC 在第三季度将其在 ANI Pharmaceuticals 的股份增加了 159.1%。CWM LLC 现在拥有 798 股这家专业制药公司的股票，价值 73,000 美元，此前在此期间又获得了 490 股。对冲基金和其他机构投资者持有该公司 76.05% 的股票。</p>
</div><h2>ANI Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>ANI Pharmaceuticals 股票表现</h2>
</div><p>NASDAQ:ANIP opened at $76.70 on Friday. The company's 50-day moving average price is $81.26 and its 200-day moving average price is $85.77. The company has a current ratio of 2.58, a quick ratio of 2.04 and a debt-to-equity ratio of 1.20. The company has a market cap of $1.72 billion, a P/E ratio of 47.06 and a beta of 0.50. ANI Pharmaceuticals, Inc. has a twelve month low of $54.10 and a twelve month high of $99.50.</p>
<div class="lb-trans"><p>NASDAQ:ANIP 周五开盘价为 76.70 美元。该公司的 50 日移动平均价格为 81.26 美元，200 日移动平均价格为 85.77 美元。该公司的流动比率为 2.58，速动比率为 2.04，债务与股本比率为 1.20。该公司的市值为 17.2 亿美元，市盈率为 47.06，贝塔值为 0.50。ANI Pharmaceuticals, Inc. 的 12 个月最低价为 54.10 美元，最高价为 99.50 美元。</p>
</div><h2>Insider Transactions at ANI Pharmaceuticals</h2>
<div class="lb-trans"><h2>ANI Pharmaceuticals 内部交易</h2>
</div><p>In other news, VP Meredith Cook sold 500 shares of the company's stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $84.33, for a total value of $42,165.00. Following the completion of the sale, the vice president directly owned 74,374 shares in the company, valued at $6,271,959.42. This represents a 0.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link. Also, Director Renee P. Tannenbaum sold 1,800 shares of ANI Pharmaceuticals stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $81.15, for a total value of $146,070.00. Following the transaction, the director owned 25,157 shares in the company, valued at approximately $2,041,490.55. The trade was a 6.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 4,322 shares of company stock worth $354,816 in the last ninety days. Insiders own 11.10% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，副总裁 Meredith Cook 在 1 月 13 日星期二出售了 500 股公司的股票。股票以平均价格 84.33 美元出售，总价值为 42,165.00 美元。交易完成后，副总裁直接持有 74,374 股公司股票，价值 6,271,959.42 美元。这代表其持股减少了 0.67%。该交易已在向证券交易委员会提交的文件中披露，具体信息可在此链接查看。此外，董事 Renee P. Tannenbaum 在 12 月 5 日星期五出售了 1,800 股 ANI Pharmaceuticals 的股票。股票以平均价格 81.15 美元出售，总价值为 146,070.00 美元。交易完成后，董事持有 25,157 股公司股票，价值约 2,041,490.55 美元。该交易使其持股减少了 6.68%。有关此销售的更多详细信息可在官方 SEC 披露中找到。过去 90 天内，内部人士共出售了 4,322 股公司股票，价值 354,816 美元。内部人士持有公司 11.10% 的股票。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>Several equities analysts have issued reports on ANIP shares. Weiss Ratings reaffirmed a &#34;hold (c+)&#34; rating on shares of ANI Pharmaceuticals in a report on Monday, December 29th. Guggenheim upped their price target on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, January 16th. Barclays initiated coverage on shares of ANI Pharmaceuticals in a research note on Tuesday, December 9th. They issued an &#34;overweight&#34; rating and a $100.00 price target on the stock. Finally, Zacks Research cut ANI Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, January 6th. Six equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, ANI Pharmaceuticals currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $103.43.</p>
<div class="lb-trans"><p>几位股票分析师对 ANIP 股票发布了报告。Weiss Ratings 在 12 月 29 日的报告中重申了对 ANI Pharmaceuticals 股票的 “持有（c+）” 评级。Guggenheim 在 1 月 16 日的研究报告中将 ANI Pharmaceuticals 的目标价从 115.00 美元上调至 124.00 美元，并给予该股票 “买入” 评级。Barclays 在 12 月 9 日的研究报告中开始覆盖 ANI Pharmaceuticals 的股票。他们对该股票给予了 “增持” 评级，并设定了 100.00 美元的目标价。最后，Zacks Research 在 1 月 6 日的报告中将 ANI Pharmaceuticals 的评级从 “强力买入” 下调至 “持有”。六位股票研究分析师对该股票给予了买入评级，三位分析师对公司给予了持有评级。根据 MarketBeat 的数据，ANI Pharmaceuticals 目前的共识评级为 “适度买入”，平均目标价为 103.43 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on ANIP</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 ANIP 的最新研究报告</strong></p>
</div><h2>About ANI Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 ANI Pharmaceuticals</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.</p>
<div class="lb-trans"><p>ANI Pharmaceuticals, Inc. 是一家总部位于美国的专业制药公司，专注于仿制药和品牌处方药的开发、生产和商业化。该公司作为一个端到端的服务提供商，提供从活性药物成分（API）生产和配方开发到成品剂型制造和包装的服务。</p>
</div><p>ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.</p>
<div class="lb-trans"><p>ANI 的产品组合涵盖了多个治疗领域的注射和口服疗法，包括内分泌学、肿瘤学、疼痛管理和呼吸护理。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than ANI Pharmaceuticals</li>
<li>Nvidia CEO Issues Bold Tesla Call</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>Buy this Gold Stock Before May 2026</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>New gold price target</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 ANI Pharmaceuticals</li>
<li>Nvidia CEO 发布大胆的特斯拉预测</li>
<li>你的银行账户不再安全</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>新的黄金价格目标</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ANIP?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 ANIP 吗？</strong> 访问 HoldingsChannel.com，获取 ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - 免费报告) 的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5JUA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=ANIP"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in ANI Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 ANI Pharmaceuticals 吗？</h2>
</div><p>Before you consider ANI Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 ANI Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ANI Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经确定了五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 ANI Pharmaceuticals 并不在名单上。</p>
</div><p>While ANI Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 ANI Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

信安金融集团降低了在 ANI 制药公司中的持股比例